Watermark
Go to Asia edition

Keryx aims for dual listing on high-growth exchanges

  • 28 Jul 2000
WESTLB and Roth Capital should complete the first simultaneous Nasdaq and Aim listing next week. The $46m-$55m IPO of Keryx Biopharmaceuticals was due to close on Tuesday, but has been postponed and will be completed imminently, a banker close to the deal said. The deal ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial
Log in

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bond Comments

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 Citi 279,044.54 1077 8.14%
2 JPMorgan 269,727.78 1175 7.87%
3 Bank of America Merrill Lynch 252,265.52 846 7.36%
4 Barclays 208,923.91 770 6.10%
5 Goldman Sachs 186,335.71 608 5.44%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 BNP Paribas 35,544.70 147 6.51%
2 JPMorgan 32,630.93 64 5.98%
3 UniCredit 29,482.91 134 5.40%
4 SG Corporate & Investment Banking 29,116.48 111 5.33%
5 Credit Agricole CIB 26,776.31 135 4.90%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 JPMorgan 11,322.29 47 9.04%
2 Goldman Sachs 10,369.68 49 8.28%
3 Citi 9,112.07 51 7.28%
4 UBS 6,515.43 25 5.20%
5 Morgan Stanley 6,436.97 42 5.14%